Sotyktu, deucravacitinib
Named-patient access overview. Sotyktu is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Sotyktu
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Sotyktu
Sotyktu (deucravacitinib) is manufactured by Bristol Myers Squibb and indicated for Moderate-to-severe plaque psoriasis in adults. It is an oral small molecule (TYK2 inhibitor) approved by the US FDA in 2022 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Sotyktu
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Sotyktu for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Sotyktu is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Sotyktu for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Sotyktu is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Sotyktu
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list deucravacitinib as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Frequently asked questions
How can I get Sotyktu if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Sotyktu for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Sotyktu through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Sotyktu. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Sotyktu through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Sotyktu to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Sotyktu to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Sotyktu cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Sotyktu?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.